Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer.
Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer.
复制标题
晚期乳腺癌患者长期他莫昔芬治疗期间的激素变化。
作者：
I. Számel;B. Vincze;I. Hindy;I. Hermann;J. Borvendég;S. Eckhardt
观察了三苯氧胺（TAM）对30例绝经后晚期乳腺癌患者血清性激素及性激素结合球蛋白（SHBG）水平的影响。为了研究垂体的“催乳素储备能力”，在TAM治疗前，然后在治疗的第2周和第8周测量促甲状腺激素释放激素（TRH）和舒必利诱导的催乳素释放。TRH（400微克静脉注射）-诱导的催乳素分泌显着抑制TAM治疗8周后，但仅在响应的情况下。最大催乳素刺激发生在TRH注射后15分钟，在癌症患者中等于5，600 +/- 800 mIU/l，8周后降至2，400 +/- 150 mIU/l。TAM没有抑制舒必利诱导的催乳素释放无论是在反应者或无反应者。
The effect of tamoxifen (TAM) on the serum levels of sexual hormones and on the sex hormone-binding globulin (SHBG) was investigated in 30 postmenopausal patients with advanced breast cancer. To study the 'prolactin reserve capacity' of the pituitary gland, thyrotrophin-releasing hormone (TRH) and sulpiride-induced prolactin release were measured prior to TAM treatment, then in the 2nd and 8th week of the therapy. The TRH (400 micrograms i.v.)-induced prolactin secretion was significantly suppressed by TAM after an 8-week treatment, but only in responding cases. Maximal prolactin stimulation occurred at the 15th min after TRH injection, being equal to 5,600 +/- 800 mlU/l in cancer patients, and decreasing to 2,400 +/- 150 mlU/l after 8 weeks. TAM did not suppress the sulpiride-inducable prolactin release either in responders or in nonresponders.